131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义

赵腾 梁军 林岩松

引用本文:
Citation:

131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义

    通讯作者: 梁军, email:liangjun1959@aliyun.com ; 林岩松, email:linys@pumch.cn
  • 基金项目:

    国家自然科学基金(30970850)

    卫生行业科研专项(201202012)

The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma

    Corresponding author: Liang Jun, email:liangjun1959@aliyun.com ; Lin Yansong, email:linys@pumch.cn
  • 摘要: 甲状腺球蛋白(Tg)是分化型甲状腺癌(DTC)患者长期随访的重要指标之一。DTC患者的血清Tg监测包括刺激性Tg(sTg)(TSH>30μIU/ml刺激状态下的Tg水平)和非刺激性Tg (TSH抑制状态下的Tg水平)测定,前者对于DTC患者的病情监测具有更高的灵敏度和特异度。目前,"清甲"治疗后sTg是DTC患者病情监测的重要手段;而131I治疗前sTg (ps-Tg)由于受残余甲状腺组织的影响,在DTC病情评估及治疗决策方面的意义尚存在争议。自2009年美国甲状腺协会的相关指南中指出ps-Tg水平可能对DTC患者的疾病状态有一定的预测作用后,近5年来有关ps-Tg与131I治疗后疾病状态与预后间关系的研究备受关注。笔者主要就ps-Tg在DTC风险评估及治疗决策中的意义进行综述。
  • [1] Eustatia-Rutten CF,Smit JW,Romijn JA,et al.Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma,a structured meta-analysis[J].Clin Endocrinol(Oxf),2004,61(1):61-74.
    [2] American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer,Cooper DS,Doherty GM,et al.Revised American thyroid association manage-ment guidelines for patients with thyroid nodules and differentiated thyroid cancer[J].Thyroid,2009,19(11):1167-1214.
    [3] 中华医学会内分泌学分会,中华医学会外科学分会内分泌学组,中国抗癌协会头颈肿瘤专业委员会,等.甲状腺结节和分化型甲状腺癌诊治指南[J].中华内分泌代谢杂志,2012,28(10):779-797.
    [4] Lima N,Cavanere H,Tomimori E,et al.Prognostic value of serial serum thyroglobulin determinations after total thyroidectomy for dif-ferentiated thyroid cancer[J].J Endocrinol Invest,2002,25(2):110-115.
    [5] Mazzaferri EL,Robbins RJ,Spencer CA,et al.A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma[J].J Clin Endocrinol Metab,2003,88(4): 1433-1441.
    [6] Bachelot A,Leboulleux S,Baudin E,et al.Neck recurrence from thyroid carcinoma: serum thyroglobulin and high-dose total body scan are not reliable criteria for cure after radioiodine treatment[J].Clin Endocrinol (Oxf),2005,62(3): 376-379.
    [7] Baloch Z,Carayon P,Conte-Devolx B,et al.Laboratory medicine practice guidelines.Laboratory support for the diagnosis and moni-toring of thyroid disease[J].Thyroid,2003,13(1):3-126.
    [8] Valle LA,Gorodeski Baskin RL,Porter K,et al.In thyroidectomized patients with thyroid cancer,a serum thyrotropin of 30μU/mL after thyroxine withdrawal is not always adequate for detecting an elevated stimulated serum thyroglobulin[J].Thyroid,2013,23(2):185-193.
    [9] Spencer CA,Takeuchi M,Kazarosyan M,et al.Serum thyroglobulin autoantibodies: Prevalence,influence on serum thyroglobulin measurement,and prognostic significance in patients with differentiated thyroid carcinoma[J].J Clin Endocrinol Metab,1998,83(4):1121-1127.
    [10] Rahmoun MN,Bendahmane I.Anti-thyroglobulin antibodies in differentiated thyroid carcinoma patients: study of the clinical and biological parameters[J].Ann Endocrinol (Paris),2014,75(1):15-18.
    [11] Durante C,Tognini S,Montesano T,et al.Clinical aggressiveness and long-term outcome in patients with papillary thyroid cancer andcirculating anti-thyroglobulin autoantibodies[J].Thyroid,2014,24(7):1139-1145.
    [12] Tsushima Y,Miyauchi A,Ito Y,et al.Prognostic significance of changes in serum thyroglobulin antibody levels of pre-and post-total thyroidectomy in thyroglobulin antibody-positive papillary thyroid carcinoma patients[J].Endocr J,2013,60(7):871-876.
    [13] 戴庆靖,匡安仁.甲状腺球蛋白抗体对电化学发光免疫分析法测定甲状腺球蛋白的影响[J].生物医学工程学杂志,2011,28(4):780-783.
    [14] Phan HT,Jager PL,van der Wal JE,et al.The follow-up of patients with differentiated thyroid cancer and undetectable thymglobulin (Tg) and Tg antibodies during ablation[J].Eur J Endocrinol,2008.158(1):77-83.
    [15] Salvatori M,Raffaelli M,Castaldi P,et al.Evaluation of the surgical completeness after total thyroidectomy for differentiated thyroid carcinoma[J].Eur J Surg Oncol,2007,33(5):648-654.
    [16] Toubeau M,Touzery C,Arveux P,et al.Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after I-131 ablation therapy in patients with differentiated thyroid cancer[J].J Nucl Med,2004,45(6):988-994.
    [17] Kim TY,Kim WB,Kim ES,et al.Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma[J].J Clin Endocrinol Metab,2005,90(3):1440-1445.
    [18] 邱忠领,罗全勇.甲状腺球蛋白与分化型甲状腺癌[J].国际放射医学核医学杂志,2009,33(2):89-92.
    [19] Piccardo A,Arecco F,Puntoni M,et al.Focus on high-risk DTC patients:high postoperative serum thyroglobulin level is a strong predictor of disease persistence and is associated to progression-free survival and overall survival[J].Clin Nucl Med,2013,38(1):18-24.
    [20] Rosario PW,Xavier AC,Calsolari MR.Value of postoperative thyroglobulin and ultrasonography for the indication of ablation and 131I activity in patients with thyroid cancer and low risk of recurrence[J].Thyroid,2011,21(1):49-53.
    [21] Kim H,Kim SJ,Kim IJ,et al.Limited clinical value of periablative changes of serum markers in the prediction of biochemical remission in patients with papillary thyroid cancer[J].Nucl Med Mol Imaging,2013,47(4):268-272.
    [22] González C,Aulinas A,Colom C,et al.Thyroglobulin as early prognostic marker to predict remission at 18-24 months in differen-tiated thyroid carcinoma[J].Clin Endocrinol (Oxf),2014,80(2):301-306.
    [23] Pacini F,Molinaro E,Lippi F,et al.Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma[J].J Clin Endocrinol Metab,2001,86(12):5686-5690.
    [24] Tourniaire J,Bernard MH,Ayzac L,et al.Serum thyroglobulin assay after total unilateral thyroid lobectomy for differentiated thyroid carcer[J].Presse Me d,1990,19(28):1309-1312.
    [25] Webb RC,Howard RS,Stojadinovic A,et al.The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer:a meta-analysis involving 3947 patients[J].J Clin Endocrinol Metab,2012,97(8):2754-2763.
    [26] Giovanella L,Ceriani L,Chelfo A,et al.Thyroglobulin assay 4 weeks after thyroidectomy predicts outcome in low-risk papillary thyroid carcinoma[J].Clin Chem Lab Med,2005,43(8):843-847.
    [27] Heemstra KA,Liu YY,Stokkel M,et al.Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma[J].Clin Endocrinol (Oxf),2007,66(1):58-64.
    [28] Hall FT,Beasley NJ,Eski SJ,et al.Predictive value of serum thyroglobulin after surgery for thyroid carcinoma[Jj.Laryngoscope,2003,113(1):77-81.
    [29] Kim MH,Ko SH,Bae JS,et al.Combination of initial stimulation thyroglobulins and staging system by revised A T A guidelines can elaborately discriminate prognosis of patients with differentiated thyroid carcinoma after high-dose remnant ablation[J].Clin Nucl Med,2012,37(11):1069-1074.
    [30] Clappuccini R,Hardouin J,Heutte N,et al.Stimulated thyroglobulin level at ablation in differentiated thyroid cancer:the impact of treatment preparation modalities and tumor burden[J].Eur J Endocrinol,2014,171(2):247-252.
    [31] Makarewicz J,Adamczewski Z,Knapska-Kucharska M.Evaluation of the diagnostic value of the first thyroglobulin determination in detecting metastases after differentiated thyroid carcinoma surgery[J].Exp Clin Endocrinol Diabetes,2006,114(9):485-489.
    [32] de Rosario PW,Guimaraes VC,Maia FF,et al.Thyroglobulin be-fore ablation and correlation with posttreatment scanning[J].Laryn-goscope,2005,115(2):264-267.
    [33] Lin Y,Li T,Liang J,et al.Predictive value of preablation stimulated thyroglobulin and thyroglobulin/thyroid-stimulating hormone ratio in differentiated thyroid cancer[J].Clin Nucl Med,2011,36(12):1102-1105.
    [34] 李田军,林岩松,梁军,等.131I治疗前刺激性Tg对乳头状甲状腺癌远处转移的预测价值[J].中华核医学与分子影像杂志,2012,32(3):189-191.
    [35] Tamilia M,Al-Kahtani N,Rochon L,et al.Serum thyroglobulin predicts thyroid remnant ablation failure with 30mCi iodine-131 treatment in patients with papillary thyroid carcinoma[J].Nucl Med Commun,2011,32(3):212-220.
    [36] Bernier MO,Morel O,Rodien P,et al.Prognostic value of an increase in the serum thyroglobulin level at the time of the first ablative radioiodine treatment in patients with differentiated thyroid cancer[J].Eur J Nucl Med Mol Imaging,2005,32(12):1418-1421.
    [37] Lee JI,Chung YJ,Cho BY,et al.Postoperative-stimulated serum thyroglobulin measured at the time of 131I ablation is useful for the prediction of disease status in patients with differentiated thyroid carcinoma[J].Surgery,2013,153(6):828-835.
    [38] Lee CW,Roh JL,Gong G,et al.Risk factors for recurrence of papillary thyroid carcinoma with clinically node-positive lateral neck[J].Ann Surg Oncol,2015,22(1):117-124.
    [39] Lin JD,Huang MJ,Hsu BR,et al.Significance of postoperative serum thyroglobulin levels in patients with papillary and follicular thyroid carcinomas[J].J Surg Oncol,2002,80(1):45-51.
    [40] Huang IC,Chou FF,Liu RT,et al.Long-term outcomes of distant metastasis from differentiated thyroid carcinoma[J].Clin Endocrinol(Oxf),2012,76(3):439-447.
    [41] Kim HJ,Lee JI,Kim NK,et al.Prognostic implications of radioiodine avidity and serum thyroglobulin in differentiated thyroid carcinoma with distant metastasis[J].World J Surg,2013,37(12):2845-2852.
    [42] Vaisman A,Orlov S,Yip J,et al.Application of post-surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma[J].Head Neck,2010,32(6):689-698.
    [43] Rosario PW,Mineiro Filho AF,Prates BS,et al.Postoperative stimulated thyroglobulin of less than 1 ng/ml as a criterion to spare low-risk patients with papillary thyroid cancer from radioactive Iodine ablation[J].Thyroid,2012,22(11):1140-1143.
    [44] Ibrahimpasic T,Nixon I J,Palmer F L,et al.Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer is there a need for ra-dioactive iodine therapy?[J].Surgery,2012,152(6):1096-1105.
    [45] Hackshaw A,Harmer C,Mallick U,et al.131I activity for remnant ablation in patients with differentiated thyroid cancer:a systemat-ic review[J].J Clin Endocrinol Metab,2007,92(1):28-38.
    [46] Mallick U,Harmer C,Yap B,et al.Ablation with low-dose radioio-dine and thyrotropin alfa in thyroid cancer[J].N Engl J Med,2012,366(18):1674-1685.
  • [1] 赵腾梁军林岩松131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义. 国际放射医学核医学杂志, 2015, 39(1): 61-66.
    [2] 南楠鲜于志群赵明朱小华 . 甲状腺球蛋白抗体与分化型甲状腺癌131I治疗效果的关系研究. 国际放射医学核医学杂志, 2021, 45(9): 545-551. doi: 10.3760/cma.j.cn121381-202007044-00094
    [3] 丁颖李文亮李强李德宇张富强丁献敏王丽君陈鸿彪贾建敏杨辉 . 分化型甲状腺癌术后首次血清刺激性Tg水平对远处转移的预测价值. 国际放射医学核医学杂志, 2019, 43(4): 308-313. doi: 10.3760/cma.j.issn.1673-4114.2019.04.003
    [4] 林岩松 . 分化型甲状腺癌131I治疗的争议与探索. 国际放射医学核医学杂志, 2022, 46(7): 389-391. doi: 10.3760/cma.j.cn121381-202206015-00196
    [5] 韩娜刘新峰司增梅李娇张莹莹王叙馥 . 分化型甲状腺癌131I治疗后TgAb由阳转阴时间与临床转归的关系. 国际放射医学核医学杂志, 2022, 46(7): 412-418. doi: 10.3760/cma.j.cn121381-202203030-00197
    [6] 殷海霞赵德善131I SPECT/CT在分化型甲状腺癌术后淋巴结转移中应用价值的研究进展. 国际放射医学核医学杂志, 2022, 46(9): 565-570. doi: 10.3760/cma.j.cn121381-202108012-00219
    [7] 张静陆奕行邓胜明章斌 . 不同剂量131I治疗中低危分化型甲状腺癌的短期疗效及长期预后的Meta分析. 国际放射医学核医学杂志, 2023, 47(12): 758-767. doi: 10.3760/cma.j.cn121381-202303033-00371
    [8] 高刘艳李素平 . 甲状腺球蛋白和甲状腺球蛋白抗体在分化型甲状腺癌诊治中的价值. 国际放射医学核医学杂志, 2020, 44(3): 196-201. doi: 10.3760/cma.j.cn121381-201812053-00009
    [9] 李娇韩娜李凤岐卢承慧杨雪林岩松王叙馥 . 肺转移性分化型甲状腺癌术后131I治疗疗效及其影响因素的分析. 国际放射医学核医学杂志, 2022, 46(7): 405-411. doi: 10.3760/cma.j.cn121381-202203031-00204
    [10] 林军缪蔚冰吴立坚汤冰131I治疗分化型甲状腺癌转移灶中甲状腺球蛋白测定和131I-全身显像的意义. 国际放射医学核医学杂志, 2006, 30(3): 161-162,167.
    [11] 侯莎莎沈婕秦岚131I全身显像及血清甲状腺球蛋白测定在分化型甲状腺癌治疗随访中的作用. 国际放射医学核医学杂志, 2013, 37(5): 269-271. doi: 10.3760/cma.j.issn.1673-4114.2013.05.004
  • 加载中
计量
  • 文章访问数:  1854
  • HTML全文浏览量:  189
  • PDF下载量:  5
出版历程
  • 收稿日期:  2015-01-06

131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义

    通讯作者: 梁军, email:liangjun1959@aliyun.com
    通讯作者: 林岩松, email:linys@pumch.cn
  • 1. 中国医学科学院北京协和医学院, 北京协和医院核医学科, 北京, 100730;
  • 2. 青岛大学附属医院肿瘤科, 青岛, 266003
基金项目:  国家自然科学基金(30970850)卫生行业科研专项(201202012)

摘要: 甲状腺球蛋白(Tg)是分化型甲状腺癌(DTC)患者长期随访的重要指标之一。DTC患者的血清Tg监测包括刺激性Tg(sTg)(TSH>30μIU/ml刺激状态下的Tg水平)和非刺激性Tg (TSH抑制状态下的Tg水平)测定,前者对于DTC患者的病情监测具有更高的灵敏度和特异度。目前,"清甲"治疗后sTg是DTC患者病情监测的重要手段;而131I治疗前sTg (ps-Tg)由于受残余甲状腺组织的影响,在DTC病情评估及治疗决策方面的意义尚存在争议。自2009年美国甲状腺协会的相关指南中指出ps-Tg水平可能对DTC患者的疾病状态有一定的预测作用后,近5年来有关ps-Tg与131I治疗后疾病状态与预后间关系的研究备受关注。笔者主要就ps-Tg在DTC风险评估及治疗决策中的意义进行综述。

English Abstract

参考文献 (46)

目录

    /

    返回文章
    返回